Triple-negative breast cancer with pathologic complete response after neoadjuvant chemoimmunotherapy complicated by immune toxicity

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

Left mastectomy on November 17 confirmed pathologic complete response, and 5-month follow-up showed no residual hepatic, dermatological, metabolic, or neurological sequelae from the treatment-related complications.

PubMed CentralRead more →

Recurrent breast cancer complicated by T-DXd-associated dermatomyositis and interstitial lung disease

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Initial tumor had weak ER/AR, PR-negative, HER2 0. Recurrence became ER/PR/AR-negative, HER2-low, PD-L1 CPS ~30.

The cancer progressed after adjuvant therapy and again after 6 cycles of gemcitabine/carboplatin. Trastuzumab deruxtecan was followed by dermatomyositis features and interstitial pneumonia, with symptoms worsening despite glucocorticoid treatment after continued exposure.

PubMed CentralRead more →

Breast cancer history with severe MSSA infective endocarditis and vascular complications

Patient Info: Anonymized, Female

Her breast cancer treatment was historical; the active episode was MSSA infective endocarditis with embolic complications, treated successfully with antibiotics, hepatic artery embolization, and aortic valve replacement, followed by asymptomatic 3-month outpatient review.

PubMed CentralRead more →

HER2-positive DCIS with KLHL11 encephalitis and pulmonary adenocarcinoma in situ

Patient Info: Anonymized, Female, Under 40 | Stage 0

Biomarkers: Breast DCIS was ER/PR positive and HER2 positive

After local breast treatment and later lung resection, she was asymptomatic on levetiracetam and tamoxifen, with no recurrent fever, seizures, or ataxia reported.

PubMed CentralRead more →

Breast Cancer: Dani's Survivor Story

Patient Info: Dani Trops, Female

As of November 2025, Dani was described as a young breast cancer survivor, advocate, and content creator discussing dating, intimacy, trust, communication, and relationship confidence after breast cancer.

Stage III Invasive Lobular Carcinoma: Stacy's Survivor Story

Patient Info: Stacy, Female | Stage III

Biomarkers: Hormone receptor-positive; HER2-negative

Stacy completed chemotherapy, mastectomy, radiation and reconstruction. She remained under regular monitoring and was taking Letrozole as part of a planned 10-year course.

Lobular Breast Cancer AllianceRead more →

HER2-positive breast cancer: brain recurrence, T-DXd liver injury, and later progression

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2-positive; hormone receptor-negative; grade 3 infiltrative breast carcinoma

Metastatic Site: brain; thoracic lymph nodes

As of October 2025, the patient had developed brain and thoracic nodal recurrence after HER2-directed treatment, experienced T-DXd-associated liver injury, progressed after later paclitaxel/trastuzumab, and died at home in December 2024 under palliative care.

PubMed CentralRead more →

Breast cancer care complicated by acute-on-chronic pulmonary embolism requiring emergency pulmonary thromboendarterectomy

Patient Info: Anonymized, Female, 40s

As of October 2025, the case focused on survival of an emergency pulmonary thromboendarterectomy during breast cancer care; breast cancer stage, subtype, treatment response, and recurrence status were not described.

PubMed CentralRead more →

Stage IIIB HER2-positive breast cancer followed by resected pancreatic ductal adenocarcinoma

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: Breast cancer HER2-amplified; ER/PR changed from positive to negative after treatment. Pancreatic markers supported a separate pancreatic cancer.

The breast cancer achieved radiological and clinical remission after multimodality HER2-directed treatment. In 2025, a separate pancreatic ductal adenocarcinoma was resected, and adjuvant gemcitabine plus albumin-bound paclitaxel was recommended.

PubMed CentralRead more →

HER2-Positive Breast Cancer: Janella's Survivor Story

Patient Info: Janella Bustamante, Female, 40s

Biomarkers: Triple-positive: estrogen-, progesterone- and HER2-fueled breast cancer

As of October 2025, Janella had completed lumpectomy, chemotherapy, radiation and HER2-targeted biological therapy for triple-positive breast cancer and was on follow-up every 3 months; the source describes life after cancer but does not explicitly state NED/cancer-free.

Cleveland ClinicRead more →

Stage IV HER2-Positive Breast Cancer: Paul's Patient Story

Patient Info: Paul Forgette, Male, 60s | Stage IV

Biomarkers: HER2-positive; triple-positive breast cancer; CHEK2 mutation

Metastatic Site: Bones; lymph nodes

By October 2025, 9 months after starting Enhertu, Paul’s Stage IV HER2-positive male breast cancer was described as dormant, not cured, with continued City of Hope care and integrative support.

City of HopeRead more →

Stage IV Triple-Negative Breast Cancer: Nicole's Patient Story

Patient Info: Nicole, Female, 40s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: liver

Nicole remained in active treatment for liver-metastatic triple-negative breast cancer, with meaningful response after switching to an antibody-drug conjugate and then undergoing mastectomy.

The Patient StoryRead more →

Invasive lobular breast cancer with dense lymphocytic infiltration treated with surgery, radiation, chemotherapy, and endocrine therapy

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER-positive/PR-negative, HER2 1+ lobular breast cancer; Ki-67 35%

At 1 year after surgery, the patient remained recurrence-free while receiving postmenopausal aromatase inhibitor endocrine therapy.

PubMed CentralRead more →

Stage IIIC ER-positive male breast cancer: mastectomy, chemotherapy, radiation, tamoxifen and abemaciclib

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: ER 90% positive; PR 60% positive; HER2 score 0; Ki-67 15%; BRCA1 and BRCA2 no pathogenic variants; CEA 2.4 ng/mL; CA15-3 13.6 U/mL

He remained on tamoxifen and dose-adjusted abemaciclib; annual follow-up imaging, including non-contrast CT, showed no local or distant relapse.

PubMed CentralRead more →

Stage IV Invasive Ductal Carcinoma: Dalitso's Patient Story

Patient Info: Dalitso, Female, Under 40 | Stage IV

Metastatic Site: bone: spine, ribs, sternum, hip sockets

Dalitso had severe Stage IV bone-metastatic breast cancer with hospice-level symptoms and later bone progression, but subsequent imaging after a new treatment approach showed no visible active disease.

The Patient StoryRead more →

PT2N0M0 breast malignant adenomyoepithelioma: disease-free after excision and radiation

Patient Info: Anonymized, Female, 50s

Biomarkers: p63-positive; E-cadherin-positive; CK7-negative on pathology re-review; ER-negative; PR-negative; HER2/neu-negative; sentinel lymph node negative, triple negative

Alive with no evidence of disease after 78 months of follow-up following wide local excision and adjuvant breast radiation.

PubMed CentralRead more →

HER2-positive Stage IV breast cancer: T-DM1 extravasation wound healed after multidisciplinary care

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER 90% positive; PR 70% positive; HER2 IHC 3+

Metastatic Site: pelvis

As of October 2025, the T-DM1 extravasation wound had almost fully healed within about 4 weeks, and the patient continued adjuvant T-DM1 through a port; longer cancer-control status was not described.

PubMed CentralRead more →

Stage IV BRCA2 Invasive Lobular Carcinoma: Marissa's Patient Story

Patient Info: Marissa, Female, Under 40 | Stage IV

Biomarkers: BRCA2 mutation; HER2-negative; PARP inhibitor resistance/progression described

Metastatic Site: bone marrow / bone; lymph nodes; skull lesions

Marissa’s breast tumors resolved after hormone blockers, but she remained in active treatment for Stage IV disease involving bone marrow/bone, lymph nodes, and skull lesions.

The Patient StoryRead more →

HER2-positive luminal B breast cancer with axillary tumor deposits: no recurrence after multimodal therapy

Patient Info: Anonymized, Female, 50s

Biomarkers: HER2-positive

After neoadjuvant therapy, mastectomy, axillary dissection, continued hormone therapy, and trastuzumab, she remained in good clinical condition with no detected recurrence.

PubMed CentralRead more →

Stage IIA ER/PR-positive mucinous breast cancer: tamoxifen plus cryoablation with no recurrence

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: ER/PR strongly positive, HER2 negative; CA15-3 and CEA remained normal during follow-up.

At approximately 32 months after cryoablation, the treated area had decreased to a less distinct 0.7 cm scar-like region, with no evidence of recurrence in either breast, axillae, or distant sites.

PubMed CentralRead more →

Stage I ER-positive PR-negative breast cancer: disease-free after lumpectomy, radiation and tamoxifen

Patient Info: Anonymized, Female, 40s | Stage I

Biomarkers: ER 2+ in 60% of tumor cells; PR-negative; HER2/neu-negative; Ki-67 5%; 0/6 lymph nodes positive

At 15 months after surgery, she was disease-free, had no complaints, and was satisfied with the surgical result.

PubMed CentralRead more →

HER2-positive breast cancer: AC-THP treatment completed after infusion-port salvage

Patient Info: Anonymized, Female, 50s

Biomarkers: HER2-positive

She completed the planned breast-cancer treatment course after successful port salvage, had no recurrence of port-site skin thinning or exposure over the next 2 years, and the port was removed in October 2024.

PubMed CentralRead more →

Breast Cancer: Josephine's Survivor Story

Patient Info: Josephine, Female, Under 40

As of October 2025, Josephine was cancer-free after melanoma in 2015 and breast cancer 2 years later, with breast cancer treatment including operations, chemotherapy, radiotherapy, and 5 years of anti-hormone therapy.

Deltra: Stage IV triple-negative breast cancer and sexual health advocacy story

Patient Info: Deltra, Female | Stage IV

Biomarkers: Triple-negative breast cancer

As of October 2025, Deltra was described as a mother of 5 living with triple-negative metastatic breast cancer and advocating for better sexual-health conversations in oncology care.